FA
REGN icon

Friess Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Friess Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-41,200
Closed -$15.4M – 145
2018
Q4 		$15.4M Sell
41,200
-8,350
-17% -$3.06M 1.32% 35
2018
Q3 		$20M Buy
49,550
+26,550
+115% +$10.1M 1.4% 33
2018
Q2 		$7.93M Buy
+23,000
New +$7.19M 0.63% 60

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Friess Associates's REGN Position: Q1 2019 in Review

Friess Associates sold out of Regeneron Pharmaceuticals (REGN) in Q1 2019, closing a stake of 41,200 shares — an estimated $15.4M sold.

Friess Associates first reported a position in REGN in Q2 2018 and held it in 3 quarters. The position peaked at $20M in Q3 2018. 718 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

  • Friess Associates reported no remaining Regeneron Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Friess Associates sold 41,200 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $15.4M.
  • Friess Associates first reported a position in Regeneron Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Friess Associates's Regeneron Pharmaceuticals position peaked at $20M in Q3 2018.
  • 718 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on Friess Associates's 13F filing for Q1 2019, filed 15 May 2019.